We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Vaccine recipient claims he suffered side effect of severe blood clot
Covid may have abated, but emerging diseases and new drug categories are keeping the analytics firm busy
German group slashes guidance by €1bn and reduces spending as it expects fewer first vaccine doses and lower boosting
Biotech blames weaker US sales after lowering full-year forecast
Call for rapid detection comes as pharma groups criticise draft WHO treaty on how to avoid another health crisis
Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic
US biotech has been struggling to overcome fall in demand for coronavirus jabs
Doubts grow over safety and effectiveness of drugs that were marketed as coronavirus treatments
Combined jab as effective as separate shots in early stage tests
Companies have yet to provide investors with convincing post-pandemic strategies
Oxford university shot expected to deliver ‘sufficient’ supply for all at-risk infants
Katalin Karikó and Drew Weissman praised for role in ‘unprecedented rate of development’ of coronavirus jabs
Brussels launches talks for mRNA jabs to augment existing contract with BioNTech/Pfizer
Big-selling molnupiravir treatment produces permanent mutations that can be passed from patient to patient
Climate change helps the spread of infectious diseases. Plus: rise in fungal infections highlights risks of antimicrobial resistance; Sydney shows how to almost eliminate HIV transmission; wait goes on for effective Long Covid treatments
At least three descendants of Omicron have scientists on alert and vaccination programmes speeding up
Drug regulator’s decision is the first step towards a new round of jabs as cases rise in the US
Preliminary studies find exposure to prevalent XBB.1.5 strain elicits antibodies to BA.2.86
Potential mutations prompts authorities to begin immunisation rollout in September
As vaccines are tweaked while new sub-variants emerge, the virus cannot be treated yet as a seasonal bug
Prominent figure in UK pandemic response becomes medical consultant at pharma group
New vaccines centre supports aim to develop jab for any new potential killer pathogen within 100 days
Move by RMT, Unite and Aslef comes as stoppage by top NHS doctors in England ends without resolution
A doctor, a model and a boxer raised millions from Covid sceptics and anti-vaxxers. Then a knock-down, drag-out brawl broke out
New treatments have had remarkable results but there are reasons to be cautious
International Edition
